Australia’s most successful manufacturer, biotechnology company CSL today reported net profit after tax of $2.64 billion for the 12 months ended 30 June 2024, up 25 percent on a constant currency basis. Net profit after tax (NPATA) was $2.91 billion, up 15 percent on revenue up 11 percent to $14.8 billion. CSL’s Chief Executive Officer…
Biotechnology giant CSL has reported net profit after tax for the six months ended December 31 of $1.9 billion, up 20 percent on the previous corresponding period. Underlying net profit was $2.02, set on revenue up 11 percent to $8.05 billion. CSL CEO and Managing Director Dr Paul McKenzie said: “Our strong first half result…
What were the five biggest stories of the week? Here’s what visitors to this site were reading. 5) AUKUS technology sharing comes a step closer Australian access to foreign technologies on a range of cutting edge industrial technologies is a step closer following progress in the US Senate to the provision of exemptions from export…
Australia’s largest manufacturer, biotechnology and vaccine producer CSL’s brand value has jumped more than 30 percent over the past year to make it the fastest growing brand in its industry, according to a new report from consultant Brand Finance. The report lists CSL’s brand value at US$1.3 billion, which is up 80 percent since 2020.…
